XJPX
7747
Market cap5.67bUSD
Oct 09, Last price
3,363.00JPY
1D
-0.33%
1Q
-5.88%
Jan 2017
184.10%
IPO
2,060.89%
Name
Asahi Intecc Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Asahi Intecc Co., Ltd. is a global enterprise dedicated to the research, manufacturing, and distribution of advanced medical devices. Its market reach extends across Japan, the United States, Europe, the Middle East, and China, with a significant international footprint. The company's diverse product range serves various medical specialties, including cardiology, where it supplies percutaneous transluminal coronary angioplasty (PTCA) guide wires, guiding catheters, balloon catheters, and penetration catheters. For peripheral, abdominal, and cerebrovascular systems, they provide specialized guide wires (including IVR guide wires and cerebrovascular system guide wires) and micro catheters. Additionally, Asahi Intecc produces guide wires and catheters vital for angiography procedures. Beyond its own brand, the company offers original equipment manufacturing (OEM) services for other medical device firms. It also manufactures a variety of medical and industrial components, such as element wires, stranded conductors, coils, tubes, and terminal processing products, specializing in the development and sale of ultra-fine stainless steel wire ropes and associated processed items. Founded in 1976 as Asahi Mini Rope Sales Co., Ltd., the company was renamed Asahi Intecc Co., Ltd. in July 1988 and is headquartered in Aichi, Japan.
Related entities
Branches
ASAHI INTECC CO. LTD.
Key people
Kenji Miyata
President, Chief Executive Officer, Chairman of Subsidiary, Representative Director · since 2024
Makoto Nishiuchi
Managing Director, Chief Digital Officer, Chief Senior Director of Medical Business, Manager of Brand Business Unit in Main Medical Business Supervision Unit · since 2024
Yuichi Iizuka
Senior Executive Officer, Manager of Customer Service Strategy Office, Manager of Domestic Sales Group in Brand Business Unit in Main Medical Business Supervision Unit, President of Subsidiary · since 2023
Tadakazu Kato
Senior Executive Officer, Chief Senior Director of Production, Chairman, General Manager and President of Subsidiary · since 2025
Munechika Matsumoto
Senior Executive Officer, Chief Director of Basic Technology Research · since 2025
Yo Nobuta
Senior Executive Officer, President & CEO of Subsidiary · since 2025
Kazuo Chiba
Executive Officer, President of Subsidiary · since 2023
Tomoya Eguchi
Executive Officer, Manager of the Regulatory Affairs and Clinical Medicine Unit in Main Medical Business Supervision Unit · since 2022
Tatsuji Higashi
Executive Officer, Manager of Device Business Unit · since 2023
Kazuaki Inukai
Executive Officer, President of Subsidiaries · since 2024
Yasuyuki Kawahara
Executive Officer, Chief Director of Quality Assurance · since 2018
Gen Nakashima
Executive Officer, President of Subsidiary · since 2023
Hideki Tamura
Executive Officer · since 2022
Ippei Yugawa
Executive Officer · since 2019
Shinjiro Otani
Manager of the President's Office, Manager of the Human Resources Development Group, Director · since 2025
Kazuhito Ishihara
Deputy Chief Director of Fundamental Technology Research, Director · since 2024
Mizuho Ito
Chief Financial Officer, Chief Director of Administration, Manager of Business Strategy Office, Director · since 2021
Masahiko Miyata
Chairman of the Board, President of Subsidiary · since 2024
Yoshinori Terai
Chief Director of New Business Development, President & Chief Executive Officer of Subsidiaries, Director · since 2023
Ryoko Fukaya
Independent Director · since 2022
Headquarters & legal address
暁町3番地100
愛知県 瀬戸市 489-0071
JP
愛知県 瀬戸市 489-0071
JP
Address
3-100, Akatsuki-cho
Seto-shi Aichi 489-0071
JP
Seto-shi Aichi 489-0071
JP
Other language
Asahi Intecc Co.,LTD.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||